Table 3.
Logistic regression analyses for bowel damage regression or arrest among patients introduced to anti-TNF before or within 3 months of t1, n = 58
| Characteristics | OR (95% CI) | p Value | AOR (95% CI) | p Value |
|---|---|---|---|---|
| Delay initiating biologics, each 10 years from onset | 0.09 (0.09–0.10) | 0.043 | 0.09 (0.09–0.10) | 0.026 |
| Montréal age, years | ||||
| A1 [≤ 17] | Reference | Reference | ||
| A2 [18–40] | 0.94 (0.32–2.77) | 0.909 | 0.47 (0.12–1.79) | 0.266 |
| A3 [> 40] | 4.33 (0.42–44.43) | 0.217 | 2.42 (0.19–31.1) | 0.497 |
| Gender | ||||
| Female | Reference | Reference | ||
| Male | 1.52 (0.54–4.26) | 0.432 | 1.94 (0.54–6.90) | 0.308 |
| Smoking at diagnosis | ||||
| Never smoker | Reference | Reference | ||
| Active smoker | 0.20 (0.04–1.03) | 0.054 | 1.45 (0.32–6.49) | 0.631 |
| Former smoker | 0.66 (0.11–4.04) | 0.650 | 0.49 (0.05–4.77) | 0.538 |
| CD duration, years | ||||
| From diagnosis to t1 | 0.97 (0.92–1.01) | 0.965 | – | – |
| Time from anti-TNF to t1, years | 0.87 (0.73–1.03) | 0.101 | 0.86 (0.69–1.06) | 0.151 |
| Time from t1 to t2, years | 1.03 (0.98–1.09) | 0.204 | ||
| Lémann index at t1 | 1.00 (0.96–1.04) | 0.868 | 1.04 (0.99–1.09) | 0.173 |
t1 Time point 1 of the Lémann index assessment, OR odds ratio, AOR adjusted odds ratio, CI confidence interval, Bio initiation of biologics